Last reviewed · How we verify
Placebo of Simvastatin
Placebo of Simvastatin is a Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development for Control arm in Phase 3 clinical trials of simvastatin (active comparator for hyperlipidemia/cardiovascular risk reduction).
This is a placebo control formulation used in clinical trials to compare against the active simvastatin drug and has no therapeutic mechanism.
This is a placebo control formulation used in clinical trials to compare against the active simvastatin drug and has no therapeutic mechanism. Used for Control arm in Phase 3 clinical trials of simvastatin (active comparator for hyperlipidemia/cardiovascular risk reduction).
At a glance
| Generic name | Placebo of Simvastatin |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
A placebo is an inert substance administered in blinded clinical trials to serve as a control comparator. In this case, it is used in Phase 3 trials of simvastatin (an HMG-CoA reductase inhibitor) to evaluate the efficacy and safety of the active drug by comparing outcomes between placebo-treated and simvastatin-treated groups.
Approved indications
- Control arm in Phase 3 clinical trials of simvastatin (active comparator for hyperlipidemia/cardiovascular risk reduction)
Common side effects
Key clinical trials
- Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis (PHASE2)
- KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism (NA)
- Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis (PHASE3)
- Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis (PHASE3)
- Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) (PHASE3)
- Effects of Simvastatin on Uterine Leiomyoma Size (PHASE2)
- Simvastatin in Secondary Progressive Multiple Sclerosis (PHASE2)
- Topic Simvastatin for Bone Regeneration (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Simvastatin CI brief — competitive landscape report
- Placebo of Simvastatin updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI
Frequently asked questions about Placebo of Simvastatin
What is Placebo of Simvastatin?
How does Placebo of Simvastatin work?
What is Placebo of Simvastatin used for?
Who makes Placebo of Simvastatin?
What development phase is Placebo of Simvastatin in?
Related
- Manufacturer: Tanabe Pharma Corporation — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Control arm in Phase 3 clinical trials of simvastatin (active comparator for hyperlipidemia/cardiovascular risk reduction)
- Compare: Placebo of Simvastatin vs similar drugs
- Pricing: Placebo of Simvastatin cost, discount & access